March 2023 Miami Breast Cancer Conference: Updates on The Number of BIA-ALCL Deaths and Diagnoses
In late March 2023, the FDA issued an update that announced the launch of a new reporting system for cases of breast implant-associated lymphoma. Earlier in March 2023 we received updates on the number of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) deaths and diagnoses in the US and worldwide.
From "UPDATE: Reports of Squamous Cell Carcinoma (SCC) in the Capsule Around Breast Implants - FDA Safety Communication" we get the following information about the new reporting system for cases of breast implant-associated lymphoma:
As of March 22, 2023, health care providers can submit case reports of SCC, various lymphomas, and any other cancers in the capsule around breast implants to the Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma (ALCL) Etiology and Epidemiology (PROFILE) Registry, a collaborative effort between the American Society of Plastic Surgeons (ASPS), the Plastic Surgery Foundation (PSF), and FDA. Health care providers can continue to submit case reports of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) to PROFILE as well.
The FDA reviews data from the PROFILE registry on an ongoing basis to gather all available information on cancers in the capsule around breast implants, and will keep the public informed on significant findings as new information becomes available.
Strictly Confidential, No Obligation.
Next, we turn to this March 6, 2023, MedPage Today news report, "Cases of Breast Implant-Associated Lymphoma Continue to Accumulate", which provided updates on the number of BIA-ALCL deaths and diagnoses in the US and worldwide.
As of late 2022, the American Society of Plastic Surgeons global tracking network had accumulated 1,333 cases of BIA-ALCL worldwide and 35 associated deaths. The total included 402 cases and eight deaths in the U.S. The FDA has received information on 59 deaths, said Kelly K. Hunt, MD, of the University of Texas MD Anderson Cancer Center in Houston, during the Miami Breast Cancer Conference.
"[BIA-ALCL] is associated with textured breast implants; it does not appear to be associated with smooth implants," she said. "It's felt to be the texturing process that results in this disease, but the pathogenesis is really not completely understood yet. There are a lot of different theories, but it's thought that production of inflammatory cytokines is involved."
We continue to handle cases of breast implant-associated lymphoma. As such, we have been monitoring the medical literature for updates on the number of BIA-ALCL deaths and diagnoses. Significant developments in the past have been put on the Breast Implants Lymphoma Cancer page of our law firm website, where we offer a Free Case Evaluation for women diagnosed with BIA-ALCL.
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects (All website content by attorney Tom Lamb)
Drug Injury Case Evaluation - Free. Confidential. No Obligation. (Case review is done by attorney Tom Lamb)